GlassScriptPhysician profile
Meghann Bybee
NPI 1982061974
$2,723.37
in general payments reported to CMS, 2019-2025
6 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $260 · 2023: $309 · 2024: $1,347 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Travel and Lodging: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.16 |
| Travel and Lodging | $546.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,492.43 | 2021-2025 | Jot Dx, Aveir, Gallant |
| Convatec INC. | $993.82 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.79 | 2022 | |
| Revance Therapeutics, INC. | $98.97 | 2025 | Daxxify |
| Kerecis Limited | $22.70 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vertex Pharmaceuticals Incorporated | $15.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghann Bybee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.